Clinical studies

We are currently running two clinical studies to demonstrate the therapeutic benefit of Cytovir CMV for the prevention of infections in bone marrow (hematopoietic stem cell) transplant patients.

More information

Anti-cancer therapy

Cytorex EBV: a revolutionary approach to treating cancer associated with the oncogenic Epstein Barr virus.

More information

Pediatric trial

Cytovir ADV, for the treatment of life-threatening adenovirus infections in children, is being tested in a clinical trial with the Institute of Child Health/Great Ormond Street Hospital.

More information

About Cell Medica

Cell Medica develops, manufactures and markets personalized cellular immunotherapeutics for infectious disease and cancer.

First pediatric patient in early stage clinical trial of Cytovir ADV
Cell Medica announces senior management appointments
Cytovir CMV - A guide to increasing the pace of implementation

Our products

Cell Medica’s proprietary production technology enables GMP compliant manufacture of antigen-specific T cells for therapeutic use in infection (Cytovir product group) and cancer (Cytorex ...

Clinical studies

Anti-cancer therapy

Pediatric trial

About Cell Medica

Press releases

Our products